Skip to main content
OpenTrials
Completed

NCT Number: NCT02713854

BAP-EB as a Predictive Tool for Endometrial Receptivity and Pregnancy Outcome of IVF Treatment

To determine the predictive value of attachment rate of human embryonic stem cells (hESC)-derived trophoblast spheroids (BAP-EB, embryo surrogate) onto endometrial epithelial cells (EEC) on success of IVF treatment and to use the model to identify EEC surface biomarkers for endometrial receptivity.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–42 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Department of Obstetrics and Gynaecology

Hong Kong, China

About this study

Study Objectives and Purpose:

There are three objectives in this study:

  • To determine the predictive value of the attachment rate of BAP-EB onto EEC on success of IVF treatment. The attachment rate of BAP-EB onto EEC of subfertile women in a natural cycle preceding the IVF cycle will be determined and correlated with the cumulative live birth rate in a subsequent stimulated IVF cycle and the derived frozen-thawed embryo transfer (FET) cycles.
  • To identify the surface molecules on EEC responsible for attaching to BAP-EB. The biotin-labeled primary EEC surface proteins that bind onto BAP-EB will be purified and identified by mass spectrometry. The bound proteins from "receptive" and "non-receptive" endometrial cell lines will be compared. The expression of the surface proteins on endometrial samples obtained in Objective 1will be correlated with their BAP-EB attachment rate.
  • To compare the BAP-EB attachment rate and expression of the attachment-related "receptive" EEC surface molecules between pre-receptive and receptive endometrium and between women with repeated implantation failure (RIF) and subfertile women due to male factors. To identify women with endometrial defects, women with RIF and failed IVF after preimplantation genetic screening (PGS) will be recruited. The latter recruitment criterion excludes RIF due to embryo aneuploidy.

Subjects:

Patients will be recruited from the Centre of Assisted Reproduction and Embryology, the University of Hong Kong at Queen Mary Hospital (HKU-QMH CARE) and at University of Hong Kong-Shenzhen Hospital (HKU-SZH CARE), the Dr Stephen Chow Chun-kay Assisted Reproduction Centre, Kwong Wah Hospital (SCCARC).

Treatment of Subjects:

Endometrial biopsies will be collected from the subjects and the attachment rate of BAP-EB onto isolated EEC will be associated with the implantation and pregnancy outcomes in IVF and the expressions of the isolated surface proteins.

Study duration: 36 months

Assessment of Safety:

  • Specification of safety parameters. Abdominal pain after endometrial aspirate
  • The methods and timing for assessing, recording, and analysing safety parameters. Subjects will be asked to contact investigators if they notice abdominal pain after endometrial aspirate
  • Procedures for eliciting reports of and for recording and reporting adverse event and intercurrent illnesses. Any abdominal pain will be documented in subjects' medical notes and they will be asked for any adverse effects and intercurrent illness when receiving IVF treatment.
  • The type and duration of the follow-up of subjects after adverse events. Subjects will be followed up in the Department of Obstetrics and Gynaecology as long as they have the adverse events.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subfertile women indicated for the first IVF or women with cryopreserved embryos at HKU-QMH CARE, HKU-SZH CARE and SCCARC
  • Women indicated for IVF treatment with a normal uterine cavity as demonstrated by saline infusion sonogram or hysteroscopy
  • Women with regular ovulatory cycles

Exclusion criteria

  • The presence of an endometrial polyp or fibroid distorting the uterine cavity
  • The presence of untreated hydrosalpinx
  • IVF treatment carried out for preimplantation genetic diagnosis
  • The use of donor oocytes

Treatment and study plan

endometrial biopsy

Procedure

An endometrial biopsy taken 2-3 months prior to IVF cycle

Primary outcomes

  1. Cumulative live birth rate

    Time frame: 36 months

    Cumulative birth rate: delivery of a live birth beyond 24 weeks of gestation in that episode of IVF treatment

Secondary outcomes

  1. Clinical pregnancy

    Time frame: 6 weeks

    presence of at least one gestational sac on ultrasound at 6 weeks

  2. Ongoing pregnancy

    Time frame: 20 weeks

    presence of at least one fetal heart pulsation on ultrasound beyond 20 weeks

  3. Implantation rate

    Time frame: 6 weeks

    Number of ultrasound detected embryonic sacs divided by the number of embryos transferred.

  4. Miscarriage rate

    Time frame: 20 weeks

    Number of miscarriages before 20 weeks divided by the number of women with a positive pregnancy test.

  5. Multiple pregnancy

    Time frame: 6 weeks

    A pregnancy with more than one gestational sac detected on ultrasound at 6 weeks

  6. Live birth rate

    Time frame: 42 weeks

    Live birth rate: delivery of a live birth beyond 24 weeks of gestation

Sponsors and collaborators

Lead sponsor

The University of Hong Kong

Other

Collaborators

  • Kwong Wah Hospital
  • The University of Hong Kong-Shenzhen Hospital

Registry information

Official study title

Human Embryonic Stem Cell-derived Trophoblastic Spheroid (BAP-EB) as a Predictive Tool for Endometrial Receptivity and Pregnancy Outcome of in Vitro Fertilization Treatment

Important dates

Study start
2017
Primary completion
2020
Study completion
2021
First posted
Mar 21, 2016
Registry last updated
Mar 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.